Aradigm Corporation (ARDM.OB) Received Milestone Payment for First Commercial Sale of SUMAVEL * DosePro *
Aradigm has gained national recognition as an emerging specialty pharmaceutical company that sets their primary focus on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases. Today, the young company took a major step towards enhancing their future with the announcement they have received a milestone $4 million payment for the first commercial sale of SUMAVEL * DosePro * to Zogenix Inc. SUMAVEL * DosePro *, a drug that combats the nagging pains of migraine attacks, was approved by the U.S. Food and Drug Administration in July 2009. Migraine is…